STRC Research

ClinicalTrials.gov

2 min read

ClinicalTrials.gov

TL;DR: NIH registry of active and completed human trials worldwide. Queried for hearing-loss + gene-therapy + AAV to track DFNB16 precedents (OTOF dual-AAV, Akouos, Sensorion, Decibel).

U.S. National Library of Medicine database of clinical studies. Essential for tracking hearing loss gene therapy trials.

What It Does

  • Registry of 400,000+ clinical studies worldwide
  • Trial status, phase, enrollment, results
  • Sponsor and investigator information
  • Intervention details (gene therapy vectors, dosing)

How to Use

Web

  1. Go to https://clinicaltrials.gov
  2. Search: “STRC hearing loss” or “inner ear gene therapy” or “OTOF”
  3. Filter: Phase, Status, Intervention Type

API

# Search for hearing gene therapy trials
curl "https://clinicaltrials.gov/api/v2/studies?query.term=hearing+loss+gene+therapy&format=json&pageSize=20"

Python

import requests
r = requests.get("https://clinicaltrials.gov/api/v2/studies", params={
    "query.term": "hearing loss gene therapy",
    "format": "json",
    "pageSize": 20
})
for study in r.json()['studies']:
    proto = study['protocolSection']
    ident = proto['identificationModule']
    status = proto['statusModule']
    print(f"{ident['nctId']}: {ident['briefTitle']} [{status['overallStatus']}]")

Verified Status

VERIFIED — No STRC-specific trials as of 2026-04. Key active hearing gene therapy trials:

  • NCT06721170: EH002 gene therapy for OTOF hearing loss (RECRUITING)
  • NCT06517888: anti-VEGF for vestibular schwannoma (RECRUITING)
  • OTOF trials are proof-of-concept for inner ear AAV delivery — directly relevant to future STRC trials.

STRC Research Usage

  • STRC Gene Therapy Landscape 2026 — monitoring trial landscape
  • No STRC trial exists yet (as of 2026-04) — STRC gene therapy is pre-clinical
  • OTOF trials (NCT06721170 EH002) demonstrate inner ear AAV delivery is feasible → directly relevant for future STRC E1659A therapy
  • STRC Gene Therapy Landscape 2026 — tracking progression toward STRC trials
  • Key trials to monitor: OTOF (proof of concept for inner ear gene therapy), TMC1, GJB2

Results (April 2026)

  • Sponsor analysis DONE: Decibel/Regeneron (DB-OTO, OTOF), Akouos/Eli Lilly (AK-OTOF), Shanghai EENT/Shu (STRC pre-clinical)
  • Active trials: NCT06721170 (EH002 OTOF gene therapy, RECRUITING) is most relevant proof-of-concept for inner ear AAV delivery
  • Next: set up automated alerts, endpoint analysis, eligibility criteria review for future STRC trial design

Connections

Graph View